Dyslipidemia in Type 2 Diabetes (0767-034)
The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Please refer to this study by its ClinicalTrials.gov identifier: NCT00547274
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|